152 related articles for article (PubMed ID: 34365656)
1. Lung transplantation outcomes after crossing low-level donor specific antibodies without planned augmented immunosuppression.
Courtwright AM; Kamoun M; Diamond JM; Kearns J; Ahya VN; Christie JD; Clausen E; Hadjiliadis D; Patel N; Salgado JC; Cevasco M; Cantu EE; Crespo MM; Bermudez CA
Clin Transplant; 2021 Nov; 35(11):e14447. PubMed ID: 34365656
[TBL] [Abstract][Full Text] [Related]
2. Clinical Outcomes of Lung Transplantation in the Presence of Donor-Specific Antibodies.
Courtwright AM; Cao S; Wood I; Mallidi HR; Kawasawa J; Moniodis A; Ng J; El-Chemaly S; Goldberg HJ
Ann Am Thorac Soc; 2019 Sep; 16(9):1131-1137. PubMed ID: 31026404
[No Abstract] [Full Text] [Related]
3. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
[TBL] [Abstract][Full Text] [Related]
4. Safety of Crossing Donor-specific Antibodies in Lung Transplantation.
Wang M; Campbell P; Lien DC; Varughese R; Weinkauf J; Nagendran J; Hirji A; Li D; Halloran K
Transplantation; 2023 May; 107(5):1172-1179. PubMed ID: 36595026
[TBL] [Abstract][Full Text] [Related]
5. Human leukocyte antigens antibodies after lung transplantation: Primary results of the HALT study.
Hachem RR; Kamoun M; Budev MM; Askar M; Ahya VN; Lee JC; Levine DJ; Pollack MS; Dhillon GS; Weill D; Schechtman KB; Leard LE; Golden JA; Baxter-Lowe L; Mohanakumar T; Tyan DB; Yusen RD
Am J Transplant; 2018 Sep; 18(9):2285-2294. PubMed ID: 29687961
[TBL] [Abstract][Full Text] [Related]
6. De-novo donor-specific anti-HLA antibodies 30 days after lung transplantation are associated with a worse outcome.
Le Pavec J; Suberbielle C; Lamrani L; Feuillet S; Savale L; Dorfmüller P; Stephan F; Mussot S; Mercier O; Fadel E
J Heart Lung Transplant; 2016 Sep; 35(9):1067-77. PubMed ID: 27373824
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure.
Kannabhiran D; Lee J; Schwartz JE; Friedlander R; Aull M; Muthukumar T; Campbell S; Epstein D; Seshan SV; Kapur S; Sharma VK; Suthanthiran M; Dadhania D
Transplantation; 2015 Jun; 99(6):1156-64. PubMed ID: 25629531
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of pre-transplant anti-HLA antibodies and their impact on outcomes in lung transplant recipients.
Park JE; Kim CY; Park MS; Song JH; Kim YS; Lee JG; Paik HC; Kim SY
BMC Pulm Med; 2018 Mar; 18(1):45. PubMed ID: 29529999
[TBL] [Abstract][Full Text] [Related]
9. Chronic lung allograft dysfunction is associated with an increased number of non-HLA antibodies.
Xu Q; Elrefaei M; Taupin JL; Hitchman KMK; Hiho S; Gareau AJ; Iasella CJ; Marrari M; Belousova N; Bettinotti M; Narula T; Alvarez F; Sanchez PG; Levvey B; Westall G; Snell G; Levine DJ; Zeevi A; Roux A
J Heart Lung Transplant; 2024 Apr; 43(4):663-672. PubMed ID: 38141896
[TBL] [Abstract][Full Text] [Related]
10. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
[TBL] [Abstract][Full Text] [Related]
11. Pre-transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death.
Fidler SJ; Irish AB; Lim W; Ferrari P; Witt CS; Christiansen FT
Transpl Immunol; 2013 Jun; 28(4):148-53. PubMed ID: 23665534
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes of sensitized lung transplant recipients after peri-operative desensitization.
Aversa M; Martinu T; Patriquin C; Cypel M; Barth D; Ghany R; Ma J; Keshavjee S; Singer LG; Tinckam K
Am J Transplant; 2021 Oct; 21(10):3444-3448. PubMed ID: 34058795
[TBL] [Abstract][Full Text] [Related]
13. The Presence of Pretransplant HLA Antibodies Does Not Impact the Development of Chronic Lung Allograft Dysfunction or CLAD-Related Death.
Zazueta OE; Preston SE; Moniodis A; Fried S; Kim M; Townsend K; Wood I; Boukedes S; Guleria I; Camp P; El-Chemaly S; Rosas IO; Chandraker A; Milford E; Goldberg HJ
Transplantation; 2017 Sep; 101(9):2207-2212. PubMed ID: 27893614
[TBL] [Abstract][Full Text] [Related]
14. Deceased donor kidney transplantation across donor-specific antibody barriers: predictors of antibody-mediated rejection.
Schwaiger E; Eskandary F; Kozakowski N; Bond G; Kikić Ž; Yoo D; Rasoul-Rockenschaub S; Oberbauer R; Böhmig GA
Nephrol Dial Transplant; 2016 Aug; 31(8):1342-51. PubMed ID: 27190362
[TBL] [Abstract][Full Text] [Related]
15. Donor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction.
Iasella CJ; Ensor CR; Marrari M; Mangiola M; Xu Q; Nolley E; Moore CA; Morrell MR; Pilewski JM; Sanchez PG; McDyer JF; Zeevi A
J Heart Lung Transplant; 2020 Dec; 39(12):1417-1425. PubMed ID: 32981841
[TBL] [Abstract][Full Text] [Related]
16. Impact of pretransplant donor-specific antibodies on kidney allograft recipients with negative flow cytometry cross-matches.
Kwon H; Kim YH; Choi JY; Shin S; Jung JH; Park SK; Han DJ
Clin Transplant; 2018 Jun; 32(6):e13266. PubMed ID: 29676812
[TBL] [Abstract][Full Text] [Related]
17. Pre-existing donor-specific antibodies are detrimental to kidney allograft only when persistent after transplantation.
Caillard S; Becmeur C; Gautier-Vargas G; Olagne J; Muller C; Cognard N; Perrin P; Braun L; Heibel F; Lefebre F; Renner V; Gachet C; Moulin B; Parissiadis A
Transpl Int; 2017 Jan; 30(1):29-40. PubMed ID: 27678382
[TBL] [Abstract][Full Text] [Related]
18. Carfilzomib versus rituximab for treatment of de novo donor-specific antibodies in lung transplant recipients.
Razia D; Hu C; Cherrier L; Nasar A; Walia R; Tokman S
Transpl Immunol; 2022 Dec; 75():101703. PubMed ID: 36049718
[TBL] [Abstract][Full Text] [Related]
19. Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation.
Clerkin KJ; Farr MA; Restaino SW; Zorn E; Latif F; Vasilescu ER; Marboe CC; Colombo PC; Mancini DM
J Heart Lung Transplant; 2017 May; 36(5):540-545. PubMed ID: 27916323
[TBL] [Abstract][Full Text] [Related]
20. Donor-specific and -nonspecific HLA antibodies and outcome post lung transplantation.
Verleden SE; Vanaudenaerde BM; Emonds MP; Van Raemdonck DE; Neyrinck AP; Verleden GM; Vos R
Eur Respir J; 2017 Nov; 50(5):. PubMed ID: 29146602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
